Michael Chi Sells 7,259 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction on Monday, February 10th. The stock was sold at an average price of $43.28, for a total transaction of $314,169.52. Following the transaction, the insider now owns 193,601 shares in the company, valued at $8,379,051.28. This represents a 3.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Chi also recently made the following trade(s):

• On Friday, January 24th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The shares were sold at an average price of $31.00, for a total value of $536,424.00.
• On Friday, January 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13.
• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.97, for a total transaction of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.00, for a total value of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $46.43 on Thursday. The company has a market cap of $10.14 billion, a P/E ratio of 105.53 and a beta of 1.35. The business’s 50 day moving average price is $30.98 and its 200-day moving average price is $23.74. Hims & Hers Health, Inc. has a fifty-two week low of $9.14 and a fifty-two week high of $46.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Crewe Advisors LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter worth about $28,000. Raleigh Capital Management Inc. raised its position in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. lifted its stake in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares during the period. Finally, Summit Securities Group LLC bought a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $38,000. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on HIMS shares. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their target price for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Piper Sandler lifted their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Finally, BTIG Research assumed coverage on Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.